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Abstract
Prescription opioid (PO) dependence is a critical health problem. Although examination of drug
cue reactivity paradigms has advanced the understanding of risk factors for relapse for a variety of
substances (e.g., cocaine, alcohol, nicotine), no PO specific drug cue paradigm has been
developed. The current study addressed this gap in the literature and evaluated the ability of a
newly developed PO drug cue paradigm to elicit subjective, physiological, and neuroendocrine
changes among PO-dependent participants (n = 20) as compared to controls (n = 17). The drug cue
paradigm included an induction script, viewing and handling paraphernalia (e.g., bottle of
oxycontin pills, pill crusher) and watching a video depicting people using POs as well as places
related to POs (e.g., pharmacies). Consistent with hypotheses, the PO group demonstrated
significant pre- to post-cue increases on subjective ratings of craving, difficulty resisting POs,
stress, and anger. The control group did not demonstrate significant changes on any of the
subjective measures. Both the PO group and the control group evidenced significant pre- to post-
cue increases in physiological responses (e.g., blood pressure, skin conductance), as expected
given the arousing nature of the drug cue stimuli. The PO group, but not the control group,
evidenced a significant pre- to post-cue increase in heart rate and salivary cortisol levels. The
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development and validation of a drug cue paradigm for POs may help inform future research and
treatment development efforts for patients with PO dependence.
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Introduction
Prescription opioid (PO) dependence represents a critical health concern in the U.S. and
internationally (Dhalla, Persaud, & Juurlink, 2011; Fischer, Nakamura, Rush, Rehm, &
Urbanoski, 2010). PO dependence has increased significantly over the past two decades
(Bagot, Heishman, & Moolchan, 2007) and recent surveys suggest that PO use is more
commonly initiated than any other drug except marijuana (SAMHSA, 2012). Approximately
14% of individuals in the U.S. general population endorse lifetime non-medical use of POs
(Back et al., 2010), a figure totaling nearly two million individuals (SAMHSA, 2011). The
rapid rise of PO dependence in recent years is also of great concern due to its associations
with serious negative outcomes, particularly unintentional overdose fatalities (Haug,
Sorensen, Gruber, & Song, 2005; Veilleux, Colvin, Anderson, York, & Heinz, 2010). In
fact, PO dependence is implicated in more overdose fatalities than heroin and cocaine
combined (Warner, Chen, Makuc, Anderson & Minino, 2007).
Advances in Treatment and Challenges Associated with PO Dependence
Recovery from PO dependence is a significant challenge for clinicians across health care
fields. Nearly 10% of individuals seeking treatment for a substance use disorder report
current PO abuse or dependence, amounting to a tenfold increase during the past decade
(SAMHSA, 2010). The societal costs of PO use disorders in the U.S. are estimated at over
$55 billion. Opioid dependence generally, and PO dependence specifically, are particularly
challenging to treat due to a variety of factors, including: withdrawal from opioid use may
be long-lasting and characterized by substantial discomfort; increased prescribing of POs for
legitimate use has increased the availability of POs for diversion in the community; and
dependence on POs may develop following legitimate use under a prescriber’s care
(Joranson et al., 2000; Katz et al., 2007; Zacny, Bigelow, Compton, Foley, Iguchi, &
Sannerud, 2003). Because many individuals who struggle with PO dependence initiated PO
use to manage chronic pain conditions under a physician’s care, the cessation of PO use may
exacerbate one’s discomfort and decrease motivation to maintain abstinence (Back et al.,
2011; Barth et al., 2013; Joranson, 2002;). While many individuals are able to complete
detoxification and abstain from PO use for short periods of time, relapse remains highly
prevalent (Tkacz, Severt, Cacciola, & Ruetsch, 2012). For example, in a recent study by
Weiss and colleagues (2011), 30% of the treatment-seeking sample of individuals with PO
dependence had received treatment prior to the current intervention. At week 16, 74% of
participants had relapsed and by week 24, 91% had relapsed. Indeed, the essential feature of
successful treatment for opioid dependence lies with relapse prevention rather than
facilitating the initial cessation of use (O’Brien, Childress, Ehrman et al., 1998; Stewart,
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2003; Tkacz, Severt, Cacciola, & Ruetsch, 2012). In summary, PO dependence is a chronic
and relapsing disease characterized by complex barriers to treatment.
One critical advancement in the treatment of opioid dependence over the past several
decades is the use of pharmacological interventions. Clinical trials investigating the efficacy
of several medications (e.g., Buprenorphine, Suboxone) alone and in combination with
psychotherapy have yielded promising results (Carroll et al., 2001; Tkacz et al., 2012; Weiss
et al., 2011). However, the generalizability of these findings to PO-dependent individuals
may be limited because they have focused primarily on heroin-dependent individuals.
Considering that PO dependence is currently 20 times more prevalent than heroin use, and
approximately twice as many individuals seek treatment for PO dependence than heroin
dependence (Office of Applied Studies, 2009), there is a great need for investigations to
identify factors that exacerbate drug craving and predict drug consumption among PO
dependent individuals.
Cue Reactivity and Relapse
Cue reactivity is a laboratory methodology in which an individual’s subjective, behavioral,
biological, and/or physiological responses to drug-related cues are measured. Previous
laboratory studies have shown that exposure to drug-related cues, as compared to neutral
cues, increases craving and induces changes in mood states and physiological measures
(Carter & Tiffany, 1999; Shi et al., 2009; Yu et al., 2007). Importantly, cue reactivity in the
laboratory has been found to predict relapse to drug use outside of the laboratory among
cocaine and nicotine-dependent individuals (Back et al., 2010; Sinha et al., 2009).
Studies of cue reactivity have given rise to a variety of theoretical models, most of which
use classical conditioning principles to explain drug cue-elicited craving and reactivity
(O’Brien et al., 1998; See, 2002; Siegel, 1999; Siegel & Ramos, 2002). These findings
suggest that, through a process of associative learning, previously neutral stimuli acquire
incentive-motivational properties following repeated pairing with drug consumption. Cue
reactivity, therefore, is a conditioned response that occurs as a result of learned association
between the cue and drug intake (Drummond, 2000). Thus, conditioned stimuli play a
critical role in sustaining ongoing drug-seeking behavior and relapse after periods of
abstinence (Childress et al., 1988; O’Brien et al., 1998; Sinha et al., 2000; Stewart, 2003).
Most studies have assessed cue reactivity among alcohol, cocaine or nicotine dependent
individuals (Drobes, 2002; Niaura et al., 1988; Reynolds & Monti, 2012) and several studies
have examined heroin dependent individuals (Childress et al., 1986a, 1986b; Daglish et al.,
2001; Sell et al., 2000; Franken et al. 1999; Powell et al., 1990). To our knowledge, there
have not been any studies examining cue reactivity among individuals with PO dependence.
This critical gap in the literature is likely due to the fact that no drug cue paradigm for POs
has been developed.
The development of a drug cue paradigm specific to PO dependent individuals is essential in
order to facilitate research aimed at identifying factors that predict relapse and testing novel
relapse prevention interventions. Therefore, the goal of this study was to assess the ability of
a newly developed PO drug cue paradigm to elicit: (1) subjective responses (e.g., craving,
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stress, negative emotion); (2) physiological reactions (heart rate, blood pressure, skin
conductance); and (3) neuroendocrine changes (cortisol) in PO-dependent participants as
compared to healthy control participants. We hypothesized that PO-dependent participants
would demonstrate greater cue-induced increases in subjective, physiological and
neuroendocrine responses compared to control participants.
Methods
Participants
Participants were non-treatment seeking, PO dependent individuals (n = 20) and healthy
control participants who did not have PO or any other substance use disorders (n = 17). PO
dependence was defined as meeting current (i.e., past 6 months) Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition (DSM-IV; American Psychiatric Association,
2000) criteria for substance dependence on opioid analgesics (e.g., oxycodone,
hydrocodone). Newspaper and other media advertisements were the primary source of
recruitment. Participants were recruited as part of a larger study on the relationship between
stress, drug cues, and the hypothalamic-pituitary-adrenal (HPA) axis.
Potential participants were initially screened by telephone and individuals meeting
preliminary eligibility criteria came into the office for a clinical assessment and a history
and physical examination. Exclusion criteria included: pregnancy or nursing; BMI ≥ 39;
major medical problems (e.g., diabetes, HIV, Addison’s or Cushing’s disease) or comorbid
psychiatric conditions (e.g., current major depressive disorder or post-traumatic stress
disorder, current or history of bipolar affective disorder or psychotic disorder) that could
effect the HPA axis; use of methadone or other opioid replacement therapies in the past
three months; use of antihypertensive medications, beta-blockers, synthetic glucocorticoid
therapy, or treatment with other agents that may interfere with stress response in the past
month; or DSM-IV criteria for substance dependence (except caffeine or nicotine) within the
past 60 days. Individuals who met criteria for abuse of other substances had to identify POs
as their primary drug of choice. Controls were excluded if they met DSM-IV criteria for
current or history of substance dependence (except caffeine or nicotine). Participants were
informed about all study procedures. IRB-approved written informed consent was obtained
before any study procedures occurred. Eligible participants (both PO and healthy controls)
were scheduled for a one-night hospital stay at a large southeastern university medical center
and testing was completed the next morning.
Assessments
Substance Use—The Structured Clinical Interview for DSM-IV (SCID; First, Spitzer,
Gibbon, and Williams, 2002) and the Mini International Neuropsychiatric Interview (MINI;
Sheehan et al., 1998) were used to assess substance use disorders (SCID) and other Axis I
psychiatric disorders (MINI). Urine drug screen tests were performed using the On Track
Test Cup® (Roche Diagnostics). Breathalyzer tests (AlcoSensor III, Intoximeters Inc., St.
Louis) were administered to test for the presence of alcohol. The Addiction Severity Index –
Lite (ASI) was administered to assess seven functional domains related to addictions,
including drug use, alcohol use, medical status, psychiatric status, family and social status,
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employment status, and legal status (McLellan, Cacciola, Alterman, Rikoon, & Carise,
2006).
Subjective Reactivity—To assess craving, stress, anger, happiness, and sadness a visual
analog scale that was derived from the Within Session Rating Scale was used (Childress,
McLellan, and O’Brien, 1986b). It was anchored with adjective modifiers from 0 = “not at
all” to 10 = “extremely”. The State-Trait Anxiety Inventory (STAI; Form Y1; Spielberger et
al., 1983), a 20-item self-report form, measured stress and anxiety on a 4-point Likert scale
(1 = “not at all” to 4 = “very much so”) immediately before the drug cue paradigm and then
at 15, 30 and 60 minutes post.
Physiological Reactivity—Heart rate (HR) was collected via electrodes along the bottom
of the participant’s ribcage and collar bone. Systolic (SBP) and diastolic blood pressure
(DBP) were measured using a GE Pro 400 Dinamap automated monitor. Mean arterial
pressure (MAP) was calculated using the formula [(2 x DBP)+SBP/3]. Normal range of
MAP is 70 – 110 mmHg. Two measurements (taken 15 minutes apart) of HR, SBP and DBP
were taken at baseline before testing began, and the average of these two measurements was
used as the baseline value. Physiological measures were then taken immediately after the
drug cue paradigm and at 15, 30 and 60 minutes post.
Neuroendocrine Assay—Unstimulated salivary samples were collected by passive drool
in polypropylene vials and immediately iced. Samples were aliquoted into 1.8 nunc tubes
and saliva was then frozen at −70°C until assayed. Samples were assayed in duplicate using
a high sensitivity salivary cortisol enzyme immunoassay system that has an intra-assay
precision (coefficient of variation, CV) of 3.35% – 3.65% with a sensitivity of <0.003 ug/dL
(Salimetrics LLC). Samples were analyzed using a PowerWave HT Microplate
Spectrophotometer in conjunction with a Precision Series Automated Liquid Handling
System (BioTek Instruments, Inc.). Salivary samples were collected immediately before the
drug cue paradigm and then at 15, 30 and 60 minutes post.
Laboratory Procedures
Three days of abstinence from alcohol and other substances (except caffeine and nicotine),
as evidence by self-report, breathalyzer and urine drug screen, were required prior to
admission for the overnight stay. Participants were admitted to the hospital at 2000h the
evening prior to testing to allow for the control of extraneous variables (e.g., sleep, caffeine
intake) that could potentially affect reactivity. Cigarette smokers were provided with a
nicotine patch upon admission. Twenty-four hour nicotine replacement therapy was
maintained throughout the hospital stay (≥ 20 cigarettes/day = 21 mg; 10–19 cigarettes/day
= 14 mg patch; 5–9 cigarettes/day = 7 mg patch).
Participants were provided a standard breakfast at 0730h and then escorted by research staff
to the laboratory for testing. Sedentary activities, such as reading, were allowed during a 60-
minute acclimation period from 0830–0930h. Pre-testing assessments were conducted at
0930h and 0945h, and testing began at 0950h.
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During testing, all participants (PO dependent and controls) underwent a 15-minute drug cue
paradigm. A variety of cue presentation modalities have been developed for other drugs of
abuse and include imaginal, in vivo, audio, video, pictorial and virtual reality techniques
(Conklin, 2006). The complex nature of drug-related cues suggests that traditional cue
reactivity techniques (e.g., pictures) may be insufficient to present the complexity of
addictive behaviors. Thus, we conducted focus groups (N=24) with individuals with PO
dependence to inquire about what types of stimuli or places trigger cravings to use POs and
incorporated that information into the development of a multi-modal PO drug cue paradigm
(Back et al., 2011). The paradigm consists of three five-minute components: (1) a five-
minute audio induction script, in which the participant listens to a recorded script that guides
them to relax and then think, in as much detail as possible, about the last time they used
POs. They were encouraged to think as specifically as possible about the PO use episode
(e.g., experiencing the feeling of chalkiness on their tongue from the pill); (2) five minutes
of viewing and handling drug paraphernalia (e.g., a sealed bottle of real oxycontin pills,
spoon, glass of water, pill crusher, straw, small square piece of aluminum foil, money, a
handout of various POs); and (3) a five-minute video depicting people using POs in a variety




Table 1 presents the demographic characteristics. As expected, two-variable χ2 tests
revealed group differences in education and employment status (χ2s > 4.9; ps < .05). No
other demographic differences were observed. One-way analyses of variance (ANOVA)
revealed significantly higher ASI subscale scores for drug use, legal status, and psychiatric
symptoms among the PO group, as compared to controls (Fs > 6.2; ps < .05).
Effects of Drug Cue on Subjective Ratings
Table 2 presents the within- and between-group findings for the subjective ratings in the PO
and control groups. One-way ANOVAs were used to investigate between group differences
in baseline subjective ratings. These findings demonstrated significantly higher subjective
ratings for stress (Figure 1), craving (Figure 2), difficulty resisting use, anger, amount
willing to pay to use, and state anxiety (STAI) as well as significant lower happiness in the
PO group compared to the control group (Fs > 3.9; ps < .055). Paired t-tests were used to
investigate pre- to post-cue changes in each of the subjective ratings. The peak post-cue
response was selected from the four time points (immediate, 15 minutes, 30 minutes, and 60
minutes) and used in all analyses. As can be seen in Table 2, the control group did not
demonstrate significant pre- to post-cue changes in any of the subjective ratings. In contrast,
the PO group evidenced significant pre- to post-cue changes on subjective ratings of craving
(Figure 1), stress (Figure 2), difficulty resisting use, and anger (ts > 2.8; ps < .05). Finally,
analysis of covariance (ANCOVA) was used to investigate the effect of the drug cue
paradigm across the two groups (PO vs. control) with the pre-cue scores entered as
covariates. Separate ANCOVAs were run for each of the subjective indices. The findings
revealed a significant group effect for the post-cue ratings of craving, stress, difficulty
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resisting use, and anger after controlling for pre-cue ratings (Fs > 13.5; ps < .01; ηp > .283),
suggesting that participants in the PO group evidenced greater craving and negative affect in
response to the drug cue paradigm than the participants in the control group (see Table 2).
Effects of Drug Cue on Physiological Reactivity
Table 3 presents the within- and between-group findings for the physiological indices in the
PO and control groups. Similar to the analyses of subjective ratings, one-way ANOVAs
were used to investigate between-group differences in baseline physiological reactivity. The
findings demonstrated significantly higher MAP and HR in the PO group compared to the
control group (Fs > 3.9; ps ≤ .05). Paired t-tests were used to investigate pre- to post-cue
changes in each measure of physiological reactivity, with the peak post-cue response being
used in all analyses. Both the PO and control groups demonstrated increased MAP and GSR
in response to the drug cue (ts > 4.9; ps < .01). However, the PO group (t = 3.3, p < .01), but
not the control group (t = 1.9; p > .05), demonstrated increased HR in response to the drug
cue. This HR finding was further supported by a significant group effect on post-cue HR in
the ANCOVA (F = 4.4; p < .05).
Effects of Drug Cue on Neuroendocrine Response
Although the baseline cortisol level was higher among the PO as compared to the control
group (Figure 3), this difference was not significant. In response to the drug cue paradigm
the PO group, but not the control group, demonstrated a significant pre- to post-cue increase
in cortisol (t = 2.3; p < .05). An ANCOVA was run for cortisol levels across the two groups
(PO vs. control) with the pre-cue scores entered as covariates. A significant group effect on
post-cue cortisol was revealed (F = 5.6; p < .05; Figure 3). The cortisol response was
reversed across the two groups with a significant increase in cortisol in the PO group and a
non-significant reduction in cortisol in the control group.
Discussion
Results indicate that the newly developed PO drug cue paradigm effectively elicits
differential subjective and biological responses among PO dependent individuals as
compared to healthy controls. To our knowledge, this is the first study to develop and
validate a drug cue paradigm specific to prescription opioids; that is, containing triggers that
are directly address POs (e.g., a bottle of opioid pills, images of pharmacies, handling a pill
crusher). Cue reactivity paradigms have contributed significantly to advancements in
addictions research for a variety of substances, including alcohol, cocaine, heroin, and
nicotine (Carter & Tiffany, 1999a,b). The current study represents a critical step toward
extending this literature in PO dependent individuals.
Consistent with cue reactivity paradigms for other substances of abuse (Carter & Tiffany,
1999a), the 15-minute PO paradigm combines three modalities of cue exposure: audio-
guided imagery, in-vivo (e.g., handling pill bottles, pill crusher), and video. At baseline, PO
dependent individuals presented with significantly more negative affect (e.g., stress, anger)
and craving. As expected, the PO group evidenced significantly greater increases in pre- to
post-cue craving, stress, anger, and inability to resist using in response to the drug cue
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paradigm compared to the control group. Stress, anger, and sadness either improved or
stayed the same following cue administration among controls. The moderate to large effect
sizes for these subjective responses are consistent with prior cue reactivity research and
suggest that subjective ratings are especially sensitive to the specificity of the cues
administered (Carter & Tiffany, 1999). Subjective results also show that the newly
developed paradigm elicited negative affect in addition to craving among PO dependent
individuals. These responses are often identified as interrelated (Schlauch, Gwynn-Shapiro,
Stasiewicz, Molnar, & Lang, 2013) and are consistent predictors of relapse among other
substance dependent populations (Hendershoot, Witkiewitz, George, & Marlatt, 2011; Li et
al., 2012).
With regard to physiological indices of reactivity, responses were largely consistent with the
incentive or appetitive-motivational model which predicts that cue reactivity will be
congruent with the drug effect (Stewart, deWit, & Eikelboom, 1984). Responses were also
consistent with prior cue reactivity research among heroin dependent individuals (Behera,
Goswami, Khastiger, & Kumar, 2003). Consistent with expectations, HR and GSR indices
were higher at baseline among the PO than control group. Participants in both the PO and
control group demonstrated significant pre- to post-cue increases in MAP and GSR.
Contrary to our hypothesis, only the HR response among the PO group was significantly
greater than the amount of response observed among the control group. The increase in
physiological response among control participants may be attributed to the arousing nature
of some elements of the drug cue paradigm. For example, subjects were exposed to drug
paraphernalia (e.g., syringe), as well as graphic video-images of individuals using POs in
various manners (e.g., injecting, crushing and snorting). In fact, normative data on the
International Affective Picture System (Lang, Ohman, & Vaitl, 1988), involving a wide
range of affective pictures with valence and arousal ratings, suggest that pictures of drug
related behaviors and cocaine paraphernalia receive moderate arousal ratings, and are
therefore likely to cause physiological arousal in most participants, including non-using
healthy controls (Cuthbert, Bradley, & Lang, 1996). Future research would benefit from
dismantling procedures or studies designed to isolate those stimuli that generate
physiological arousal only in PO dependent individuals and not in control participants.
As hypothesized, only the PO dependent group evidenced a significant pre- to post-cue
salivary cortisol increase. Among the control group, cortisol levels decreased slightly from
pre- to post-cue administration. In prior drug cue paradigm research, post-cue elevations in
cortisol have been found to be indicative of a stress response that is correlated with drug
craving, and predictive of future relapse (Back et al., 2010; Fatseas et al., 2011). These
findings emphasize the utility of examining neuroendocrine correlates of drug cue reactivity.
Further, these findings suggest that measures of HPA function were consistent with
participants’ subjective and physiological responses, lending further support to the validity
of the drug cue paradigm developed here.
The development and validation of a PO-specific cue paradigm has potential utility in
extending advances in drug abuse research to the study of PO use disorders. As an example
of potential future applications for the current paradigm, cue reactivity paradigms have been
successfully used to elucidate neural substrates and networks implicated in the craving
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response for an array of substances including nicotine, cocaine, and alcohol (Cunningham &
Anastasio, 2013; Engelmann et al., 2012; Lou et al., 2012; Mainz et al., 2012; Schacht,
Anton, & Myrick, 2013), as well as to examine potential gender differences in cue-elicited
craving (Saladin et al., 2012). Further, these paradigms have demonstrated utility in
predicting substance use behaviors – including self-initiated abstinence, latency to use, and
relapse – among a variety of substance dependent populations (Conklin, Parzynski, Salkeld,
Perkins, & Fonte, 2012; Fatseas et al., 2011; Garland, Carter, Ropes, & Howard, 2012;
Shiffman et al., 2013). Similarly, as with cue reactivity paradigms for other substances of
abuse (e.g., Modesto-Lowe & Kranzler, 1999), the current paradigm may be applied to
investigate the effects of pharmacological interventions (e.g., buprenorphine, suboxone,
oxytocin), on cue-induced and stress-induced craving.
Limitations
Several limitations of the current study should be noted. First, this was the initial validation
of the PO cue reactivity paradigm and the findings are in need of replication with a larger
sample of PO dependent individuals. In addition, the PO group was comprised of non-
treatment seeking individuals. As such, the findings may not be generalizable to treatment-
seeking individuals. All participants had abstained from PO use for at least three days prior
to their participation in the study. Acute abstinence has been noted as limitation of cue
paradigms for other substances (e.g., Adams & Munafo, 2013); experience of mild PO
withdrawal symptoms may have influenced reactivity.
Conclusions
In light of the continuing epidemic rise in misuse, abuse, and dependence on POs, the
development of cue reactivity paradigms that are specific to POs is needed to help enhance
assessment, treatment and relapse prevention. The cue reactivity paradigm developed and
validated by the current study is one such tool with the potential for empirical and clinical
utility to address the problem of PO dependence.
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• Prescription opioid (PO) dependence is a critical health problem
• Drug cue reactivity paradigms have the advanced understanding of substances
• Present study assessed PO drug cue in PO dependent and healthy participants
• PO group demonstrated pre to post cue increases in subjective/physiological
indices
• Findings support utility of a PO specific drug cue paradigm for understanding
PO
Back et al. Page 14























Subjective stress response to the drug cue paradigm among individuals with prescription
opioid dependence vs. controls.
Note. Baseline = immediately pre drug cue paradigm. Immediate = immediately post drug
cue paradigm.15 min, 30 min and 60 min = post drug cue paradigm.
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Subjective craving response to the drug cue paradigm among individuals with prescription
opioid dependence.
Note. Baseline = immediately pre drug cue paradigm. Immediate = immediately post drug
cue paradigm.15 min, 30 min and 60 min = post drug cue paradigm.
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Cortisol response to the drug cue paradigm among individuals with prescription opioid
dependence vs. controls.
Note. Baseline = immediately pre drug cue paradigm. Immediate = immediately post drug
cue paradigm.15 min, 30 min and 60 min = post drug cue paradigm.
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